Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (AldaraR)
- 1 June 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 150 (6) , 1198-1201
- https://doi.org/10.1111/j.1365-2133.2004.05993.x
Abstract
CD30+ anaplastic large cell lymphoma is a primary cutaneous lymphoproliferative disorder with a high rate of spontaneous regression (almost 25%). The suggested therapies are radiation, surgery and methotrexate. We describe two patients with nonregressing primary cutaneous CD30+ T-cell lymphoma that was successfully treated with topical imiquimod 5% cream (Aldara, 3M) three times weekly for 6 weeks. In both cases we obtained complete clinical remission, confirmed by histology. No recurrences were observed during the following 8 months. We consider that topical application of an immune response modifier, such as imiquimod, could be a good alternative to other potentially more dangerous or aggressive treatments.Keywords
This publication has 13 references indexed in Scilit:
- Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapyJournal of the American Academy of Dermatology, 2001
- Topical immunomodulators—progress towards treating inflammation, infection, and cancerThe Lancet Infectious Diseases, 2001
- Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six casesBritish Journal of Dermatology, 2001
- Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trialJournal of the American Academy of Dermatology, 2001
- Topical imiquimod treatment of a cutaneous melanoma metastasisJournal of the American Academy of Dermatology, 2000
- Immunomodulatory and pharmacologic properties of imiquimodJournal of the American Academy of Dermatology, 2000
- Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatmentBlood, 2000
- Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and ImiquimodCellular Immunology, 1999
- Treatment of genital warts with an immune-response modifier (imiquimod)Published by Elsevier ,1998
- Th2 Cytokine mRNA Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders: Successful Treatment With Recombinant Interferon-γJournal of Investigative Dermatology, 1996